HRTX announced exciting new results in early January that 90% of patients receiving HTX-011 and over-the-counter pain meds did not need opioids for post-op pain through 72 hours after surgery, compared to 51%, 40%, and 22% of patients receiving HTX-011, bupivacaine, or placebo alone. The company's U.S. marketing application seeking approval for HTX-011 plus meloxicam is currently under FDA review with an action date of April 30.
top of page
bottom of page